Open AccessMedicine

Rivastigmine for Alzheimer's disease.

J. Birks, L. Chong, J. Evans

2015.9.22Drug and Therapeutics Bulletin

DOI: 10.1002/14651858.cd001191.pub4

tlooto Summary

Rivastigmine is the second cholinesterase inhibitor marketed for symptomatic treatment of mild to moderately severe Alzheimer's dementia, and follows donepezil.

Abstract

Abstract is not available.

Citation format

BIRKS, J.; CHONG, L.; EVANS, J. Rivastigmine for alzheimer's disease. Drug and Therapeutics Bulletin, 2015, 38 2: 15–6.